SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Cooper HS. Surgical pathology of endoscopically removed malignant polyps of the colon and rectum. Am J Surg Pathol 1983; 7: 61323.
  • 2
    Morson BC, Whiteway JE, Jones EA, Macrae FA, Williams CB. Histopathology and prognosis of malignant colorectal polyps treated by endoscopic polypectomy. Gut 1984; 25: 43744.
  • 3
    Haggitt RC, Glotzbach RE, Soffer EE, Wruble LD. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology 1985; 89: 32836.
  • 4
    Cranley JP, Petras RE, Carey WD, Paradis K, Sivak MV. When is endoscopic polypectomy adequate therapy for colonic polyps containing invasive carcinoma? Gastroenterology 1986; 91: 41927.
  • 5
    Christie J. P. Polypectomy or colectomy? Management of 106 consecutively encountered colorectal polyps. Am Surg 1988;54: 939.
  • 6
    Muto T, Sawada T, Sugihara K. Treatment of carcinoma in adenomas. World J Surg 1991; 15: 3540.
  • 7
    Morson BC, Bussey HJR, Samoorian S. Policy of local excision for early cancer of the colorectum. Gut 1977; 18: 104550.
  • 8
    Coverlizza S, Risio M, Ferrari A, Fenoglio-Preiser CM, Rossini FP. Colorectal adenomas containing invasive carcinoma. Pathologic assessment of lymph node metastatic potential. Cancer 1989;64: 193747.
  • 9
    Nivatvongs S, Rojanasakul A, Reiman HM, Dozois RR, Wolff BG, Pemberton JH, et al. The risk of lymph node metastasis in colorectal polyps with invasive adenocarcinoma. Dis Colon Rectum 1991; 34: 3238.
  • 10
    Masaki T, Muto T. Predictive value of histology at the invasive margin in the prognosis of early invasive colorectal carcinoma. J Gastroenterol 2000; 35: 195200.
  • 11
    Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor “budding” in patients with colorectal cancer. Dis Colon Rectum 1993; 36: 62735.
  • 12
    Ono M, Sakamoto M, Ino Y, Moriya Y, Sugihara K, Mutom T, et al. Cancer cell morphology at the invasive front and expression of cell adhesion-related carbohydrate in the primary lesion of patients with colorectal carcinoma with liver metastasis. Cancer 1996; 78: 117986.
  • 13
    Shiozaki H, Oka H, Inoue M, Tamura S, Monden M. E-cadherin mediated adhesion system in cancer cells. Cancer 1996; 77: 160513.
  • 14
    Kadowaki T, Shiozaki H, Inoue M, Tamura S, Oka H, Doki Y, et al. E-cadherin and α-catenin expression in human esophageal cancer. Cancer Res 1994; 54: 2916.
  • 15
    Jawhari A, Jordan S, Poole S, Browne P, Pignatelli M, Farthing JG. Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival. Gastroenterology 1997; 112: 4654.
  • 16
    Takayama T, Shiozaki H, Inoue M, Tamura S, Oka H, Kadowaki T, et al. Expression of E-cadherin and α-catenin molecules in human breast cancer tissues and association with clinicopathological features. Int J Oncol 1994; 5: 77580.
  • 17
    Dorudi S, Sheffield JP, Poulsom R, Northover JMA, Hart IR. E-cadherin expression in colorectal cancer—an immunocytochemical and in situ hybridization study. Am J Pathol 1993; 142: 98186.
  • 18
    Takayama T, Shiozaki H, Doki Y, Oka H, Inoue M, Yamamoto M, et al. Aberrant expression and phosphorylation of β-catenin in human colorectal cancer. Br J Cancer 1998; 77: 60513.
  • 19
    Gunji N, Oda T, Todoroki T, Kanazawa N, Kawamoto T, Yuzawa K, et al. Pancreatic carcinoma—correlation between E-cadherin and α-catenin expression status and liver metastasis. Cancer 1998; 82: 164956.
  • 20
    Shimazui T, Schalken JA, Giroldi LA, Jansen CFJ, Akaza H, Koiso K, et al. Prognostic value of cadherin-associated molecules (α-, β-, and γ-catenins and p120 catenin) in bladder tumors. Cancer Res 1996; 56: 41548.
  • 21
    Morita N, Uemura H, Tsumatani K, Cho M, Hirao Y, Okajima E, et al. E-cadherin and α-, β-, and γ-catenin expression in prostate cancers: correlation with tumour invasion. Br J Cancer 1999; 79: 187983.
  • 22
    Gunthert U, Stauder R, Mayer B, Terpe HJ, Finke L, Friedrichs K. Are CD44 variant isoforms involved in human tumor progression? Cancer Surveys 1995; 24: 1941.
  • 23
    Wielenga V, Heider KH, Offerhaus GJA, Adorf GR, van den Berg FM, Pofnta H, et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993; 53: 47546.
  • 24
    Tanabe K, Ellis LM, Saya H. Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet 1993; 341: 7256.
  • 25
    Mulder J, Kruyt PM, Sewnath M, Oosting J, Seldenrijk CA, Weidema WF, et al. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 1994; 344: 14702.
  • 26
    Mulder J, Wielenga VJM, Polak MM, van den Berg FM, Adorf GR, Herrlich P, et al. Expression of mutant p53 protein and CD44 variant proteins in colorectal tumorigenesis. Gut 1995; 36: 7680.
  • 27
    Masaki T, Mori T, Matsuoka H, Sugiyama M, Atomi Y. Endoscopy: colonoscopic treatment of colon cancers. Surg Oncol Clin North Am 2001; 10: 693708.
  • 28
    Hugh TJ, Dillon SA, Taylor BA, Pignatelli M, Poston GJ, Kinsella AR. Cadherin-catenin expression in primary colorectal cancer: a survival analysis. Br J Cancer 1999; 80: 104651.
  • 29
    Murant SJ, Handley J, Stower M, Reid N, Cussenot O, Maitland NJ. Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer 1997; 33: 26371.
  • 30
    Garcia del Muro X, Torregrosa A, Munoz J, Castellsague X, Condom E, Vigues F, et al. Prognostic value of the expression of E-cadherin and b-catenin in bladder cancer. Eur J Cancer 2000; 36: 35762.
  • 31
    Bankfalvi A, Terpe HJ, Breukelmann D, Bier B, Rempe D, Pschadka G, et al. Immunophenotypic and prognostic analysis of E-cadherin and β-catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44. Histopathology 1999; 34: 2534.
  • 32
    Wielenga VJM, Smits R, Korinek V, Smit L, Kielman M, Fodde R, et al. Expression of CD44 in APC and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 1999; 154: 51523.